Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$70.84
-1.2%		$74.21
$38.00
▼
$123.75
$689.27M-5.27222,355 shs65,837 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-1.48%-6.88%-2.09%-6.58%+84.49%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$70.84
-1.2%		$74.21
$38.00
▼
$123.75
$689.27M-5.27222,355 shs65,837 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-1.48%-6.88%-2.09%-6.58%+84.49%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
3.00
Buy$143.83103.44% Upside

Current Analyst Ratings Breakdown

Latest DRUG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeMarket Perform
8/20/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/19/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$145.00
8/17/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$147.00
7/21/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/1/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$145.00
(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/A$8.33 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$8.74M-$2.08N/AN/AN/AN/A-12.46%-12.30%N/A

Latest DRUG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/17/2026Q3 2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$1.2230-$0.17+$1.0530-$0.17N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/A
122.00
122.00

Institutional Ownership

CompanyInstitutional Ownership
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
40.52%

Insider Ownership

CompanyInsider Ownership
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
42.66%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/A9.73 million5.58 millionNot Optionable

Recent News About These Companies

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Average Rating of "Buy" by Brokerages
August 30 at 2:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30991619
What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?
August 27, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2981315/what-makes-bright-minds-biosciences-inc-drug-a-strong-momentum-stock-buy-now?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_10-2981315
Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
August 26, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2980303/wall-street-analysts-see-a-97-01-upside-in-bright-minds-biosciences-inc-drug-can-the-stock-really-move-this-high?cid=cs-stocknewsapi-ft-fundamental_analysis|consensus_price_target-2980303
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Buy" from Analysts
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-bright-minds-biosciences-inc-nasdaq-drug-receives-average-recommendation-of-buy-from-analysts-2026-08-25/
What is HC Wainwright's Estimate for DRUG FY2026 Earnings?
August 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30977392
Bright Minds Biosciences (NASDAQ:DRUG) Upgraded to Hold at Wall Street Zen
August 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30975160
Wall Street Zen Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to Hold
August 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-bright-minds-biosciences-nasdaqdrug-to-hold-2026-08-22/
What is HC Wainwright's Forecast for DRUG FY2026 Earnings?
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-forecast-for-drug-fy2026-earnings-2026-08-21/
HC Wainwright Reaffirms Buy Rating for Bright Minds Biosciences (NASDAQ:DRUG)
August 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30973401
Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from HC Wainwright
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/bright-minds-biosciences-nasdaqdrug-earns-buy-rating-from-hc-wainwright-2026-08-19/
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5.9% - Should You Buy?
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/bright-minds-biosciences-nasdaqdrug-shares-up-59-should-you-buy-2026-08-18/
BTIG Research Reiterates "Buy" Rating for Bright Minds Biosciences (NASDAQ:DRUG)
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/btig-research-reiterates-buy-rating-for-bright-minds-biosciences-nasdaqdrug-2026-08-17/
Bright Minds Biosciences (NASDAQ:DRUG) Issues Quarterly Earnings Results
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/bright-minds-biosciences-nasdaqdrug-issues-quarterly-earnings-results-2026-08-14/
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet
August 10, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2971895/wall-street-analysts-think-bright-minds-biosciences-inc-drug-could-surge-97-4-read-this-before-placing-a-bet?cid=cs-stocknewsapi-ft-fundamental_analysis|consensus_price_target-2971895
Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials
August 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934041-bright-minds-stock-bmb-101-center-stage-phase-3-pivotal-trials
Bright Minds Biosciences (DRUG) to Post Quarterly Earnings on Thursday
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/bright-minds-biosciences-drug-to-post-quarterly-earnings-on-thursday-2026-08-06/
Perceptive Advisors LLC Sells 71,746 Shares of Bright Minds Biosciences Inc. $DRUG
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-perceptive-advisors-llc-sells-71746-shares-of-bright-minds-biosciences-inc-drug-2026-08-02/
Vistagen Appoints Douglas J. Williamson to its Board of Directors
July 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/31/3336795/0/en/vistagen-appoints-douglas-j-williamson-to-its-board-of-directors.html
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
July 23, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2959210/wall-street-analysts-see-a-107-53-upside-in-bright-minds-biosciences-inc-drug-can-the-stock-really-move-this-high?cid=cs-stocknewsapi-ft-tale_of_the_tape|consensus_price_target-2959210
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy
July 22, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2958470/all-you-need-to-know-about-bright-minds-biosciences-inc-drug-rating-upgrade-to-strong-buy?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2958470
Why Bright Minds Biosciences Inc.’s (DRUG) Stock Is Up 5.02%
July 9, 2026  |  aaii.comA

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
Hims & Hers Health logo with a two-toned teal and coral capsule pill on a matching gradient background.
The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic
By Jessica Mitacek | August 5, 2026
Cardinal Health branded boxes on pallets sit amid automated conveyor systems in a distribution warehouse.
Cardinal Health Earnings: Can Perfection Get Priced In Twice?
By Chris Markoch | August 12, 2026
Three-panel image showing a refrigerated delivery truck, vials packed in ice, and a worker in a cold storage warehouse.
GLP-1 Demand Is Creating a New Dividend Angle in These 4 Logistics Stocks
By Chris Markoch | August 4, 2026
Bright Minds Biosciences stock logo

Bright Minds Biosciences NASDAQ:DRUG

$70.84 -0.89 (-1.24%)
As of 04:00 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas